$21.94
+0.9
(+4.28%)▲
3.14%
Downside
Day's Volatility :4.15%
Upside
1.04%
80.77%
Downside
52 Weeks Volatility :82.69%
Upside
10.01%
Period | Nurix Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 70.23% | 6.5% | 0.0% |
6 Months | 167.68% | 7.1% | 0.0% |
1 Year | 123.59% | 9.8% | 0.0% |
3 Years | -28.46% | 14.2% | -20.2% |
Market Capitalization | 1.4B |
Book Value | $5.76 |
Earnings Per Share (EPS) | -2.92 |
Wall Street Target Price | 27.91 |
Profit Margin | -264.84% |
Operating Margin TTM | -401.42% |
Return On Assets TTM | -25.98% |
Return On Equity TTM | -52.33% |
Revenue TTM | 62.3M |
Revenue Per Share TTM | 1.1 |
Quarterly Revenue Growth YOY | -60.6% |
Gross Profit TTM | -145.9M |
EBITDA | -172.2M |
Diluted Eps TTM | -2.92 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.78 |
EPS Estimate Next Year | -2.84 |
EPS Estimate Current Quarter | -0.63 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 27.21%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 37.4M | - |
Net Income | -9.4M | - |
Net Profit Margin | -25.18% | - |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 31.1M | ↓ 16.91% |
Net Income | -21.7M | ↑ 130.15% |
Net Profit Margin | -69.74% | ↓ 44.56% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 17.8M | ↓ 42.73% |
Net Income | -43.2M | ↑ 99.28% |
Net Profit Margin | -242.66% | ↓ 172.92% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 29.8M | ↑ 66.95% |
Net Income | -117.2M | ↑ 171.02% |
Net Profit Margin | -393.93% | ↓ 151.27% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 38.6M | ↑ 29.84% |
Net Income | -166.0M | ↑ 41.68% |
Net Profit Margin | -429.87% | ↓ 35.94% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 77.0M | ↑ 99.31% |
Net Income | -143.9M | ↓ 13.31% |
Net Profit Margin | -186.98% | ↑ 242.89% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 12.7M | ↑ 87.01% |
Net Income | -35.3M | ↓ 15.28% |
Net Profit Margin | -278.55% | ↑ 336.33% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 30.7M | ↑ 141.83% |
Net Income | -21.8M | ↓ 38.33% |
Net Profit Margin | -71.03% | ↑ 207.52% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 18.5M | ↓ 39.8% |
Net Income | -37.0M | ↑ 69.73% |
Net Profit Margin | -200.26% | ↓ 129.23% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 15.2M | ↓ 17.91% |
Net Income | -42.0M | ↑ 13.45% |
Net Profit Margin | -276.77% | ↓ 76.51% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 16.6M | ↑ 9.41% |
Net Income | -41.5M | ↓ 1.04% |
Net Profit Margin | -250.33% | ↑ 26.44% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 12.1M | ↓ 27.09% |
Net Income | -44.5M | ↑ 7.29% |
Net Profit Margin | -368.39% | ↓ 118.06% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 45.4M | - |
Total Liabilities | 82.2M | - |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 44.0M | ↓ 2.97% |
Total Liabilities | 101.8M | ↑ 23.73% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 396.3M | ↑ 799.8% |
Total Liabilities | 106.1M | ↑ 4.24% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 476.8M | ↑ 20.29% |
Total Liabilities | 134.5M | ↑ 26.77% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 416.8M | ↓ 12.59% |
Total Liabilities | 113.1M | ↓ 15.92% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 364.5M | ↓ 12.53% |
Total Liabilities | 164.0M | ↑ 45.09% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 370.2M | ↓ 11.18% |
Total Liabilities | 96.1M | ↓ 15.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 350.6M | ↓ 5.28% |
Total Liabilities | 90.7M | ↓ 5.62% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 308.2M | ↓ 12.1% |
Total Liabilities | 74.4M | ↓ 18.0% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 364.5M | ↑ 18.28% |
Total Liabilities | 164.0M | ↑ 120.56% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 312.7M | ↓ 14.23% |
Total Liabilities | 143.9M | ↓ 12.26% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 511.0M | ↑ 63.44% |
Total Liabilities | 140.3M | ↓ 2.49% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -31.7M | - |
Investing Cash Flow | 40.0M | - |
Financing Cash Flow | 529.0K | - |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 601.0K | ↓ 101.9% |
Investing Cash Flow | 8.5M | ↓ 78.75% |
Financing Cash Flow | 126.0K | ↓ 76.18% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -80.0K | ↓ 113.31% |
Investing Cash Flow | -254.4M | ↓ 3093.69% |
Financing Cash Flow | 339.0M | ↑ 268966.67% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -84.4M | ↑ 105356.25% |
Investing Cash Flow | -108.3M | ↓ 57.45% |
Financing Cash Flow | 153.9M | ↓ 54.61% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -159.8M | ↑ 89.42% |
Investing Cash Flow | 27.2M | ↓ 125.12% |
Financing Cash Flow | 117.2M | ↓ 23.84% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -48.5M | ↑ 27.66% |
Investing Cash Flow | 43.8M | ↓ 20.32% |
Financing Cash Flow | 1.5M | ↓ 1197.04% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -18.5M | ↓ 61.88% |
Investing Cash Flow | 43.8M | ↑ 0.0% |
Financing Cash Flow | 25.0K | ↓ 98.31% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -41.1M | ↑ 122.71% |
Investing Cash Flow | 22.8M | ↓ 48.04% |
Financing Cash Flow | 1.7M | ↑ 6716.0% |
Sell
Neutral
Buy
Nurix Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Nurix Therapeutics Inc | 2.83% | 167.68% | 123.59% | -28.46% | 10.68% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Nurix Therapeutics Inc | NA | NA | NA | -2.78 | -0.52 | -0.26 | NA | 5.76 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Nurix Therapeutics Inc | Buy | $1.4B | 10.68% | NA | -264.84% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Nurix Therapeutics Inc
Revenue is down for the last 2 quarters, 16.58M → 12.09M (in $), with an average decrease of 27.1% per quarter
Netprofit is down for the last 2 quarters, -41.51M → -44.54M (in $), with an average decrease of 7.3% per quarter
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 215.0%
BlackRock Inc
Redmile Group, LLC
Baker Bros Advisors LP
Deep Track Capital, LP
State Street Corporation
ARK Investment Management LLC
nurix is a science-focused company that is committed to bringing novel, first-in-class therapies to patients. nurix is a leader in discovering a new class of drugs that work by modulating e3 ubiquitin ligases within the ubiquitin proteasome system (ups). the ups is a regulatory network that controls protein stabilization and degradation – a function vital to the healthy life of a cell – offering therapeutic opportunities in multiple disease areas. nurix’s scientific team has established an innovative drug discovery platform to identify selective inhibitors or activators of the ups, enabling the development of novel therapeutics that can restore normal cellular homeostasis. nurix was founded by internationally recognized experts in the ups field and received its initial funding from leading life science investors, third rock ventures and the column group. in 2015, nurix entered into a multi-year strategic collaboration with celgene to discover and develop next-generation therapies targe
Organization | Nurix Therapeutics Inc |
Employees | 284 |
CEO | Dr. Arthur T. Sands M.D., Ph.D. |
Industry | Health Technology |
A Spac I Acquisition Corp
$21.94
+4.28%
Keyarch Acquisition Corp
$21.94
+4.28%
Connexa Sports Technologies Inc
$21.94
+4.28%
Us Value Etf
$21.94
+4.28%
First Wave Biopharma Inc
$21.94
+4.28%
Global X Msci Next Emerging
$21.94
+4.28%
Fat Projects Acquisition Corp
$21.94
+4.28%
Capital Link Global Fintech
$21.94
+4.28%
Applied Uv Inc
$21.94
+4.28%